In The News Posted February 22, 2019 Share Posted February 22, 2019 TAIPEI, Taïwan, 22 février 2019 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) (« Foresee »), a annoncé aujourd'hui les résultats préliminaires de son étude clinique de phase 3 du FP-001 LMIS (suspension injectable de mésylate de leuprolide) 25 mg, une étude ouverte portant... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.